Qualcomm, Inc. (QCOM) Teams with Boehringer Ingelheim Pharmaceuticals to Improve COPD Treatment Outcomes
In a recent news release, Qualcomm, Inc. (NASDAQ: QCOM), through subsidiary Qualcomm Life, Inc., announced a new collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. to develop a connectivity solution for the RESPIMAT® inhaler, the platform inhaler for Boehringer Ingelheim’s family of respiratory therapies. The collaborative effort will aim to improve chronic obstructive pulmonary disease (COPD) treatment outcomes. “Qualcomm Life is committed to powering the Internet of Medical Things to ultimately enable intelligent care to be delivered wherever the patient may be,” Rick Valencia, president of Qualcomm Life, stated in the news release. “We are excited to be collaborating with an industry…







